Paper AS13

Dynamic Survival Model for Monitoring Resistance Mutations in Targeted Therapy: Advancing Precision Medicine in Oncology

Hong Zheng, Bayer Inc., Canada

ABSTRACT

Targeted therapies have revolutionized cancer treatment, offering patients more personalized and effective options. However, the development of resistance mutations poses significant challenges to long-term treatment efficacy. Recently, global health agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have begun to request resistance mutation analysis for targeted therapies in certain new drug applications. The dynamic nature of cancer presents ongoing challenges, particularly the emergence of acquired resistance mutations following the initial treatment response. In addressing this critical issue, a time-varying Cox proportional hazards model was developed to evaluate and monitor genetic resistance mutations in patients undergoing targeted therapy. This model accounts for longitudinal changes in mutation status and their association with time-to-event endpoints. Incorporating comprehensive longitudinal genetic data aims to provide valuable insights into the evolving landscape of resistance mechanisms. This not only enhances the understanding of treatment resistance but also represents significant advancement towards more comprehensive precision medicine approaches in oncology, ultimately improving patient outcomes.

Keywords: targeted therapy, resistance mutation, time-varying Cox model, precision medicine, oncology

1. INTRODUCTION

1.1 BACKGROUND

The advent of targeted therapies has marked a significant milestone in cancer treatment, offering patients more personalized and potentially more effective treatment options. These therapies are designed to interfere with specific molecular targets that are critical for tumor growth and progression, often resulting in higher efficacy and lower toxicity compared to conventional chemotherapy (Sawyers, 2004). However, the dynamic nature of cancer often leads to the development of resistance mutations, posing significant challenges in long-term treatment efficacy (Holohan et al., 2013).

1.2 THE CHALLENGE OF RESISTANCE MUTATIONS

Resistance to targeted therapies can be broadly categorized into two types: intrinsic (pre-existing) and acquired (developed during treatment) resistance (Wang X et al., 2019). While intrinsic resistance can often be identified through pre-treatment genetic testing, acquired resistance presents a more complex challenge. Patients may develop acquired resistance mutations following targeted therapy, potentially leading to relapse even after an initial complete response (Camidge et al., 2014).

1.3 THE NEED FOR DYNAMIC MONITORING

Given the evolving nature of cancer and its response to treatment, there is a critical need for real-time tracking of genetic alterations that may impact treatment outcomes. Traditional statistic models of genetic analysis fail to capture the dynamic changes occurring over treatment time. This limitation has led to an increased focus on developing more sophisticated methods for monitoring resistance mutations throughout treatment.

1.4 REGULATORY LANDSCAPE

Recognizing the importance of understanding and addressing resistance mutations, global health agencies, including the FDA and the EMA, have begun to request resistance mutation analysis for targeted therapies in certain New Drug Application (NDA) submissions. This regulatory requirement underscores the growing emphasis on comprehensive genetic profiling in cancer treatment and drug development.

1.5 STUDY OBJECTIVES

This paper presents a novel approach to monitoring resistance mutations in targeted therapy using a dynamic survival model. Specifically, it employs a time-varying Cox proportional hazards model to evaluate and monitor genetic resistance mutations, accounting for longitudinal changes in mutation status and their association with time-to-event endpoints. Our objectives are:

1. To develop a robust statistical framework for analyzing longitudinal genetic data in the context of targeted cancer therapies.
2. To assess the impact of emerging resistance mutations on patient outcomes, particularly progression-free survival.
3. To provide a tool that can inform adaptive treatment strategies and contribute to more personalized approaches in precision oncology.

2. METHODOLOGY

2.1 DATA SIMULATION

A simulation was conducted to contain patient characteristics and survival outcomes for 1,000 subjects. The simulation incorporated various baseline covariates and generated progression-free survival (PFS) times. Each subject's characteristics, including sex, age group, race, disease group, and ECOG performance status, were randomly assigned using Bernoulli and table distributions. The PFS time was generated from an exponential distribution. Additionally, the mutation time was randomly determined within the PFS duration.

It is essential to organize the data in a counting process style (Therneau & Grambsch, 2000). This approach allows for the incorporation of time-varying covariates and a more nuanced understanding of the evolving genetic landscape of each patient's cancer.

2.2 STATISTICAL MODEL: TIME-VARYING COX PROPORTIONAL HAZARDS MODEL

A time-varying Cox proportional hazards model was employed to investigate the relationship between changing mutation status and clinical outcomes. This is an extension of the standard Cox proportional hazards model that allows for the incorporation of covariates that change over time during the follow-up period (Fisher & Lin, 1999).

The model is presented by (Annabel Webb, et al. 2022):

$$h_i(t) = h_0(t)e^{x_i\beta + z_i(t)\gamma}$$

where:

- $h_i(t)$ is the hazard function, for subject i at time t
- $h_0(t)$ is the baseline hazard function
- x_i is a vector of time-fixed covariates, for subject i
- $z_i(t)$ is a vector of time-varying covariates, for subject i at time t
- β and γ are vectors of regression coefficients for time-fixed and time-varying covariates, respectively

2.3 DATA ANALYSIS

2.3.1 MODEL BUILDING

To assess the impact of potential resistance mutations, a Cox proportional hazards model was constructed with time-varying covariates. A time-varying covariate modelled the presence of resistance mutations. This covariate was set to 0, so long as no resistance mutation was detected. It was changed to 1 after the first occurrence of resistance mutations.

2.3.2 COVARIATES

The model included the following baseline covariates:

- Gender
- Age group
- Race
- Cancer diagnosis
- Stage of disease at initial diagnosis
- Baseline Eastern Cooperative Oncology Group (ECOG) performance status

2.3.3 STATISTICAL ANALYSIS

The analysis was performed using SAS/STAT® software (version 9.4, SAS Institute Inc., Cary, NC). The PHREG procedure was used to fit the time-varying Cox model. The SAS code for the main analysis is as follows:

```
Ods Output ParameterEstimates=HR;
Proc Phreg Data=data1;
       Class STATUS (ref ='0')
```

```
        AGEGRP (ref ='0')
        SEX (ref ='M')
        RACE (ref ='White')
        CHISTG (ref ='0-I')
        DIAGPST (ref ='CNS')
        ECOG (ref='0')/param=ref;
        Model (StartP, EndP)*CNS(1)=STATUS AGEGRP SEX RACE CHISTG DIAGPST ECOG
        /risklimits;
Run;
```

`StartP` and `EndP` define the time intervals for each subject, and `CNS` serves as the censoring indicator. `STATUS` represents the time-varying covariate for resistance mutation status.

2.3.4 Results on Simulated Data

Based on the simulated records of 1,000 patients, the adjusted hazard ratio for progression-free survival (PFS), after the detection of an acquired resistance mutation, was 2.632 (95% CI: [2.106, 3.287]). This demonstrates a significant association between the emergence of the acquired resistance mutation and decreased progression-free survival (PFS)

3. Discussion

3.1 Interpretation of Results

The dynamic survival model offers a powerful tool for monitoring resistance mutations in real time. By incorporating longitudinal genetic data, it provides valuable insights into the landscape of evolving resistance mechanisms. The results demonstrate that the emergence of resistance mutations is associated with a significant decrease in progression-free survival, highlighting the clinical importance of ongoing genetic monitoring during targeted therapy.

3.2 Insights for Clinical Practice

This approach has several valuable insights for clinical practice:

1. Personalized Treatment Adaptation: Timely identification of emerging resistance mutations enables clinicians to adapt treatment strategies proactively. This could involve switching to alternative targeted therapies, combination approaches, or other treatment modalities before clinical progression becomes evident.
2. Improved Patient Monitoring: Incorporating regular genetic testing into patient follow-up allows clinicians to gain a more comprehensive understanding of each patient's disease status and treatment response.
3. Informed Decision-Making: The ability to quantify the impact of specific resistance mutations on progression-free survival can aid in shared decision-making between clinicians and patients regarding treatment continuation or changes.

3.3 Insights for Advancing Drug Development

The model offers valuable insights for pharmaceutical research and development:

1. Resistance Pattern Identification: Pharmaceutical companies can use this model to better understand resistance patterns, potentially informing the development of next-generation targeted therapies or combination strategies designed to overcome specific resistance mechanisms.
2. Clinical Trial Design: The insights gained from this model could inform the design of more adaptive clinical trials, potentially leading to more efficient drug development processes.
3. Biomarker Development: The identification of early genetic changes associated with treatment resistance could lead to the development of new biomarkers for treatment response and resistance.

3.5 Limitations

While the model represents a significant advancement in monitoring resistance mutations, there are several limitations to be addressed:

1. Sampling Frequency: The accuracy of the model depends on the frequency of genetic sampling. More frequent sampling could provide greater resolution but may suffer practically and be costly.
2. Tumor Heterogeneity: As the model is, based on ctDNA analysis, it may not capture the full extent of tumor heterogeneity, particularly in cases where certain subclones are not well-represented in the circulation.
3. Functional Validation: Not all detected genetic alterations may confer functional resistance. Further research is required to correlate genetic changes with functional impacts on treatment response.

3.6 Future Directions

Future research directions should focus on:

1. Validation across different cancer types and targeted therapies to assess the generalizability of the model.
2. Integration with other clinical and molecular data, such as pharmacokinetics and immune markers, to enhance the model's predictive power.
3. Exploration of machine learning approaches to improve the identification and prediction of resistance patterns.
4. Investigation of the model's utility in guiding combination therapies or sequencing of targeted agents.

4. Summary

The dynamic survival model represents a significant advancement in precision medicine for oncology. By providing a more comprehensive understanding of treatment resistance, this approach has the potential to improve patient outcomes through more adaptive and personalized treatment strategies. The model's ability to incorporate real-time genetic data aligns with the evolving landscape of cancer care, where treatment decisions are increasingly based on fluctuating molecular.

The integration of this model into clinical practice could lead to more timely interventions, potentially extending the duration of treatment benefits and improving the quality of life for patients undergoing targeted therapies. Furthermore, its application in drug development and regulatory processes may accelerate the advancement of new therapies designed to overcome specific resistance mechanisms.

As the complexities of cancer biology and treatment resistance continue to be discovered, tools similar to this dynamic survival model will play a crucial role in translating genetic insights into actionable clinical decisions. Future research should focus on refining and expanding this approach, ultimately contributing to the ongoing evolution of precision oncology and the improvement of patient outcomes.

5. References

Annabel Webb, et al. Cox models with time-varying covariates and partly-interval censoring–A maximum penalised likelihood approach, 2022, https://onlinelibrary.wiley.com/doi/full/10.1002/sim.9645

Camidge, D. R., Pao, W., & Sequist, L. V. (2014). Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nature Reviews Clinical Oncology, 11(8), 473-481 https://pubmed.ncbi.nlm.nih.gov/24981256/

Fisher, L. D., & Lin, D. Y. (1999). Time-dependent covariates in the Cox proportional-hazards regression model. Annual Review of Public Health, 20, 145-157 https://pmc.ncbi.nlm.nih.gov/articles/PMC6015946/

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 13(10), 714-726 https://www.nature.com/articles/nrc3599

Sawyers, C. L. (2004). Targeted cancer therapy. Nature, 432(7015), 294-297 https://www.nature.com/articles/nature03095

Therneau, T. M., & Grambsch, P. M. (2000). Modeling Survival Data: Extending the Cox Model. Springer, New York

Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141-160. doi: 10.20517/cdr.2019.10. Epub 2019 Jun 19. PMID: 34322663; PMCID: PMC8315569. https://pmc.ncbi.nlm.nih.gov/articles/PMC8315569/

ACKNOWLEDGMENTS

I gratefully acknowledge the project team for their contributions to the development of this model:

Kui Shen
Shalini Chaturvedi
Lingsong Yun
Alexander Tchourbanov
Saskia Standler
Josua Boeser
Lea Zittlau

CONTACT INFORMATION

Author Name: Hong Zheng
Bayer Inc.
2920 Matheson Blvd E, Mississauga ON L4W 5R6 Canada
E-mail: hong.zheng@bayer.com
Web: http://www.bayer.ca